期刊
FUTURE MEDICINAL CHEMISTRY
卷 13, 期 16, 页码 1317-1339出版社
Newlands Press Ltd
DOI: 10.4155/fmc-2020-0393
关键词
abemaciclib; CDK4; CoMFA; CoMSIA; MD simulation; 3D-QSAR
资金
- National Natural Science Foundation of China [81872744]
- Shandong Provincial Natural Science Foundation [ZR2019MH046]
The study focused on exploring the structure-activity relationship of CDK4 inhibitor analogs and designing potent CDK4 inhibitors for breast cancer therapy. By establishing a 3D quantitative structure-activity relationship model and conducting molecular dynamics simulation studies, valuable insights were gained for developing novel CDK4 inhibitors. Four novel inhibitors with satisfactory predicted binding affinity to CDK4 were successfully designed based on the findings.
Aim: CDK4 is a promising target for breast cancer therapy. This study aimed to explore the structure-activity relationship of CDK4 inhibitor abemaciclib analogs and design potent CDK4 inhibitors for breast cancer treatment. Methods & results: A faithful 3D quantitative structure-activity relationship model was established by molecular docking, comparative molecular field analysis and comparative molecular similarity index analysis based on 56 abemaciclib analogs. Molecular dynamics simulation studies revealed the key residues of the interaction between CDK4 and inhibitors. Four novel inhibitors with satisfactory predicted binding affinity to CDK4 were designed. Conclusion: The 3D quantitative structure-activity relationship and molecular dynamics simulation studies provide valuable insight into the development of novel CDK4 inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据